Matrix metalloproteinases (MMPs) are central to tissue remodelling; however, little is known about the temporal pattern and differential regulation of hepatic MMP expression in the course of chronic human liver disease. Using quantitative reverse transcription-PCR ELISA assays, we studied hepatic mRNA expression of MMP
INTRODUCTION
In chronic liver disease, tissue injury induces a sustained wound-healing response. This process is characterized by proliferation of myofibroblast-like cells mainly derived from hepatic stellate cells (HSCs), resulting in extensive remodelling of the hepatic extracellular matrix (ECM). Fibrosis is thought to develop as a consequence of an MMPs are secreted as proenzymes, which are activated by cell-surface-associated cleavage mechanisms. MMPs are specifically inhibited by a physiologically occurring family of tissue inhibitors of metalloproteinases (TIMP) [7, 8] . In many tissues, TIMPs are co-expressed with MMPs and contribute to the regulation of local metalloproteinase activity [5] . An increased hepatic TIMP expression may thus account for reduced metalloproteinase activity and is thought to be important for hepatic fibroproliferation [9, 10] .
The regulation of MMP expression in chronic liver disease has mainly been studied in experimental models. MMP-3 and -13 expression was described during experimental induction of cirrhosis in rats [11, 12] . An early up-regulation of the expression of both MMP-3 and -13 was followed by a decline to initial levels in later stages of cirrhosis. Following bile duct ligation in rats, Kossakowska et al. [13] reported increased gelatinase activity (MMP-2 and -9).
In human liver cirrhosis of different aetiologies, increased expression of MMP-2 was found [14] [15] [16] . In hepatitis C virus (HCV)-induced cirrhosis, we have shown recently [17, 18] that hepatic expression of MMP-2 and -7 mRNA is increased in cirrhosis as compared with healthy controls. Thus currently available data suggest that MMPs may have a role in cirrhosis development, but a comprehensive description of MMP regulation in human liver disease is still lacking.
In this study, patients with chronic hepatitis C and HCV-induced liver cirrhosis were chosen as a model of chronic human liver disease. Hepatic mRNA expression of a wide panel of MMPs was quantitatively examined and compared with the disease stage, notably MMP-1 (interstitial collagenase/collagenase 1), MMP-2 (gelatinase A/72 kDa type IV collagenase), MMP-3 (stromelysin 1), MMP-7 (matrilysin), MMP-9 (gelatinase B/92 kDa type IV collagenase), MMP-10 (stromelysin 2), MMP-11 (stromelysin 3), MMP-13 (collagenase 3) and MMP-14 (membrane type-1-MMP).
METHODS

Study subjects and sample collection
Patients (n = 29) with chronic HCV infection who underwent diagnostic liver biopsy were studied. Part of the material gained during needle biopsy was used for this study. Biopsy samples were homogenized immediately and stored at − 70
• C. An additional group of seven patients who underwent liver transplantation for HCV-induced end-stage liver cirrhosis was included. Liver tissue was taken from the explanted livers. Liver slices were cut into portions immediately after excision and frozen to − 70
• C. Liver tissue samples from ten patients undergoing hepatic resection for metastatic colon tumours served as controls. Control tissue was taken from resected liver lobes and was carefully chosen from regions distant from the tumour.
Blood samples were collected at the time of biopsy, transplantation or operation. Blood was collected in evacuated tubes (Monovette 02.1063; Sarstedt, Essen, Germany), allowed to clot for 1 h at room temperature and centrifuged at 1600 g at 4
• C for 15 min. Serum was frozen to − 70
• C within 2 h after collection. The distribution of polymorphic alleles of the MMP-3 promoter was analysed in separate patients. To calculate the numbers of patients needed, we performed a power calculation including the following parameters: carriage rate for the MMP-3(− 1171)*5A allele (76 %) and carriage rate for the MMP-3(− 1171)*6A allele (68 %). To detect an expected difference of 10 % in the carriage rate, a minimum of 100 patients with chronic hepatitis C was needed. For the polymorphism study, the groups consisted of 199 healthy blood donors without evidence of chronic liver disease or fibrotic liver disease of other origin, 105 chronic hepatitis C patients without cirrhosis and 52 patients with HCV-induced cirrhosis. All persons were unrelated Caucasians presenting either to the blood bank or to the hepatology outpatient clinic at the Medizinische Hochschule Hannover.
All patients and controls were informed about the rationale and the possible risks of the study and gave their written informed consent before inclusion. The research has been carried out in accordance with the Declaration of Helsinki. The study protocol has been approved by the Local Ethics Committee at the Medizinische Hochschule Hannover.
Histological evaluation
The activity of inflammation and fibrosis in liver tissue was quantified according to the hepatitis activity index [19] . Briefly, hepatic inflammation was scored by assessing interface hepatitis, confluent necrosis, spotty necrosis and portal inflammation. Scoring points were summed for the correlation analysis. Fibrosis staging was scored from 0-6 points.
Biochemical parameters
The Biotrak TM TIMP-1, TIMP-2 and MMP-9 human ELISA systems (Amersham Biosciences, Freiburg, Germany) were used for determining circulating TIMP-1 and pro-MMP-9 concentrations in heparinized plasma (TIMP-1, dilution 1/40; MMP-9, dilution 1/20) and serum (TIMP-2, dilution 1/5). Analytical evaluations of MMP and TIMP assays using samples from healthy volunteers were published recently [20, 21] . Pro-MMP-13/active MMP-13 values in serum samples (dilution 1/20) were determined using the Biotrak TM MMP-13 human ELISA system. The Bindazyme TM Pro-MMP-1, Pro-MMP-2 and Pro-MMP-3 Enzyme Immunoassay Kits (Binding Site Ltd., Birmingham, U.K.) were employed for the determination of pro-MMP serum concentrations. The antibodies used in this kit were raised to the proenzyme form of the enzymes. Serum samples were diluted 1/20 (for MMP-2 and -3) and 1/4 (for MMP-1). Hyaluronic acid 'CHUGAI' (Chugai Diagnostics Science Co. Ltd, Tokyo, Japan) was used for the determination of serum hyaluronate (dilution 1/20).
Isolation of mRNA from liver tissue
Approx. 1 mg of liver tissue was homogenized in 1 ml of DNA/RNA Stabilization Reagent for Blood/Bone Marrow ® (Roche Diagnostics, Mannheim, Germany) and stored at − 70
• C. Extraction of mRNA was performed using a standard protocol (mRNA Isolation Kit for Blood/Bone Marrow ® ; Roche Diagnostics). RNA was quantified using the RiboGreen ® RNA Quantitation Kit (MoBiTec, Göttingen, Germany) on a F-2000 fluorescence spectrophotometer (Hitachi, Japan). mRNA (2.5 ng) was applied on to a single reverse transcription-PCR (RT-PCR) assay.
Competitive RT-PCR
Competitive RT-PCR was performed using the Titan One Tube RT-PCR System ® (Roche Diagnostics) using standard conditions. The following primers were em- Primer sequences for TIMP-1, -2 and -3 have been published previously [17] .
Fixed amounts of in vitro synthesized competitor RNA were added to each assay. The primer pairs were designed to bind to both cDNA of competitor RNA and natural mRNA origin. Internal sequence differences of both cDNAs enable hybridization with different capture probes for ELISA detection. For the purpose of validation and calibration of the procedure, varying amounts of in vitro transcribed RNA (10 5 , 10 6 , 10 7 , 10 8 and 10 9 molecules) equal to the target mRNA were co-amplified with 10 6 molecules of competitor RNA for quantification of MMPs. Concentrations of in vitro transcribed RNA were determined photometrically at 260/280 nm. For labelling of PCR products, digoxigenin-11-dUTP (final concentration 6 µM; Roche Diagnostics) was added to be incorporated during amplification.
Quantification of PCR products
For quantification of amplified cDNA, an ELISA procedure (Enzymun Test ® ; Roche Diagnostics) was performed on an automated ES-300 analyser (Roche Diagnostics) according to the manufacturer's instructions as described previously [17, 22] . First, different biotinylated oligonucleotides for hybridization with amplified cDNA of sample or competitor RNA origin were used as capture probes to bind PCR products to the solid phase. The following biotinylated probes (wild-type capture probe, competitor capture probe; sequence differences are underlined) were used:
In a second step, peroxidase-conjugated antibodies against digoxigenin were added. Following addition of the chromogen 2,2 -azinobis-(3-ethylbenzothiazoline-6-sulphonic acid), the absorbance at 405 nm was measured. This procedure of separate hybridization with different capture probes yields signals equivalent to the amount of cDNA of sample or competitor RNA origin. Results are expressed as the ratio of these signals (cDNA/ cDNA competitor ). Varying amounts of template in combination with a fixed amount of a competitor should yield a linear curve in a double-logarithmic plot expressing the amount of a varying template on one scale and the ratio of both PCR products (template/competitor) on the other. The number of molecules/ng of mRNA were retrieved from the calibration curves. Data for each calibration curve were calculated using linear regression. One calibration curve was performed for each run.
Evaluation of the RT-PCR assay
To provide precision data, RNA isolation and subsequent competitive RT-PCR ELISA from liver tissue were performed eight times. Mean values, S.D. and coefficients of variation from pooled hepatic mRNA were calculated. The evaluation of MMP-2, -7 and -9 in comparison with their specific inhibitors has been published previously [17] .
Cloning of standards
As described previously [23] , the following cDNA regions were cloned in pBluescript KS+ (Stratagene, La Jolla, CA, U.S.A.): nt 826-1097 of MMP-1, nt 1279-1665 of MMP-2, nt 830-1024 of MMP-3, nt 64-858 of MMP-7, nt 1319-1938 of MMP-9, nt 806-1000 of MMP-10, nt 688-1053 of MMP-11 and nt 357-583 of GAPDH cDNA. For the cloning of MMP-13 cDNA (GenBank ® accession number NM_002427), we amplified the cDNA region from nt 242-547 and for MMP-14 (GenBank ® accession number NM_004995) nt 1064-1472 were cloned. nt 213-611 were cloned for procollagen type 1 α-1 chain (GenBank ® accession number Z74615), the cDNA region from nt 559-1006 was amplified for the cloning of procollagen type IV α-1 chain (COL4A1) cDNA (GenBank ® accession number M10940), and nt 718-1324 in case of laminin B1 chain (GenBank ® accession number M61916).
For the construction of internal standards, several bp substitutions were introduced into the capture probe binding region. Purification of plasmid clones, in vitro transcription and preparation of standard and competitor RNA solutions were performed as described previously [22, 24] .
MMP-3 promoter polymorphism analysis
The MMP-3(− 1171) promoter polymorphism is characterized by two alleles, the first having a run of five adenosines (5A) and another with six adenosines (6A) at position − 1171 relative to the transcriptional start site. The region that contains the polymorphic site was amplified as described previously [25] . Primer sequences were 5 -TCTCATTCCTTTGATGGGGGGAAAGA-3 (upstream) and 5 -GGAATTCACATCACTGCCA-CCACT-3 . The 5A-containing allele was recognized by the restriction enzyme AspI (Roche Diagnostics), which gave products of 100 bp and 20 bp, whereas the 6A allele resisted the digestion and gave a product of 120 bp.
Genomic DNA was isolated from 200 µl of blood using the High Pure DNA Purification Kit ® (Roche Diagnostics). PCR was performed with Taq DNA polymerase (Qiagen, Hilden, Germany) using standard procedures in a total assay volume of 50 µl. The digested products for restriction-fragment-length polymorphism were fractionated by vertical PAGE on 15 % (w/v) gels. DNA fragments were visualized by silver staining [26] .
Statistics
Data were analysed using the statistical software package SPSS 11.0 for Windows. Mann-Whitney's U-test, the Kruskal-Wallis test, and the calculation of Spearman (R) rank correlation coefficients were performed. Differences were considered to be significant at P values < 0.05.
Results of the polymorphism study were analysed by comparison of allele frequencies (ratio of test allele to total alleles) and the carriage rates (number of individuals with at least one copy of the test allele) in the different populations. Increases in genotype, allele frequency and carriage rate were analysed by χ 2 significance test using 2 × 2 contingency tables [27] . Odds ratio (OR) and the confidence interval (95 %) of the OR were calculated (OR 1+ − 1.96/χ ).
RESULTS
Evaluation of the competitive RT-PCR assays
Intra-assay variation was assessed from mRNA extractions and subsequent competitive RT-PCR and automated ELISA runs using pooled samples from human liver. Evaluation data are shown in Table 1 . Coefficients of variation were calculated to be approx. 20 %, but increased for parameters with low-level expression. Corresponding data for MMP-2, -7 and -9 and TIMP-1, -2 and -3 have been reported previously [17] . Coefficients of variation were between 10 and 30 %.
Hepatic MMP mRNA expression in chronic hepatitis C
Hepatic expression of the different MMPs from normal liver through chronic hepatitis C to end-stage cirrhosis was examined. GAPDH expression was similar in all samples studied and did not change throughout the course of chronic hepatitis C (GAPDH mRNA expression: 1.0 × 10 6 + − 0.6 × 10 6 RNA equivalents/ng of mRNA in normal livers, 1.1 × 10 6 + − 0.3 × 10 6 RNA equivalents/ng of mRNA in chronic hepatitis C and 1.0 × 10 6 + − 0.2 × 10 6 RNA equivalents/ng of mRNA in end-stage liver cirrhosis). Figure 1 shows the hepatic mRNA expression of MMP-1, -2, -3, -7, -9, -11, -13 and -14. Expression levels were highly variable in human liver with an increase of three logarithmic steps from lowest-to strongestexpressed MMPs. The mean overall expression rates were highest for MMP-2 and − 7 > MMP-9 > MMP-1, -11 and -13 > MMP-3 and -14. MMP-10 was not detectable in the liver samples (results not shown).
Interestingly, several MMP groups exhibiting coordinated regulation patterns were identified. In Figure 2 , the median MMP values of the different patient groups are plotted as the fold increase compared with healthy controls. The first cluster of MMPs, comprising MMP-1, -2, -7 and -14, shows a continuously increasing mRNA expression with disease progression, reaching the highest values in decompensated end-stage cirrhosis (Figure 2a) . Up-regulation of hepatic mRNA expression varied from 14-fold for MMP-2, 25-fold for MMP-7, 66-fold for MMP-1 and 80-fold for MMP-14. In contrast, a second group of MMPs, namely MMP-9, -11 and -13, showed a transient up-regulation during the course of the disease, with decreasing gene expression in end-stage cirrhosis (Figure 2b ). Of the MMPs examined, only MMP-3 did not show major expression changes throughout the course of chronic hepatitis C. Collagen type I and IV and laminin, as well as TIMP-1, -2 and -3, were studied for comparison. Their expression was similar to the first MMP cluster (MMP-1, -2, -7 and -14), although changes were less impressive.
Figure 1 Hepatic MMP mRNA levels in normal controls, chronic hepatitis C and liver cirrhosis
Hepatic mRNA was isolated from ten normal livers (N), 29 biopsies from chronic hepatitis C patients and seven explanted end-stage cirrhotic livers (Ci). Chronic hepatitis C samples were histologically staged for fibrosis: stage 0 (F 0 ), n = 16; stages 1-4 (F 1−4 ), n = 9; and stages 5-6 (F 5/6 ), n = 4. mRNA levels were assayed using competitive RT-PCR and are presented in RNA equivalents/ng of total mRNA. Box plots are given with horizontal lines for the medians, boxes indicate the 25th-75th percentiles, bars represent the extremes without consideration of outliers and circles indicate the outliers. Multivariate analysis revealed significant differences within the following groups: P < 0.0001 (MMP-2, -7 and -14), P = 0.001 (MMP-9), P < 0.01 (MMP-11), P = 0.01 (MMP-13), and P < 0.05 (MMP-1).
Circulating pro-MMPs
To test whether circulating MMP concentrations reflect the hepatic expression pattern in chronic hepatitis C, we measured circulating proenzyme concentrations in corresponding serum/plasma samples from normal controls and patients (Figure 3 ). Assays were available for the following MMPs: pro-MMP-1, -2, -3, -9 and -13. Circulating pro-MMP-13 levels from normal controls and patients were found to be below the detection limit using the Biotrak TM assay. Significantly altered levels during the course of chronic hepatitis C were shown for MMP-2 and, interestingly, for MMP-3. Median values (2.5th-97.5th percentiles) for normal controls compared with cirrhosis for MMP-1, -2, -3 and -9 were 16 (3-42) µg/l and 13 
Figure 3 Circulating pro-MMP levels in normal controls, chronic hepatitis C and cirrhosis
Serum/plasma samples were measured using the Biotrak TM MMP-9 and Quantikine TM assays for proenzymes of MMP-1, -2 and -3. Patients were classified according to the disease stage as described in the legend to Figure 1 . Multivariate analysis demonstrated overall significance with P < 0.0001 for MMP-2 and P < 0.01 for MMP-3.
show a clear separation of values between cirrhotic and pre-cirrhotic stages for MMP-2. We did not detect any significant differences between early fibrotic and nonfibrotic stages.
Hepatic expression of MMPs compared with hepatic expression of ECM parameters, histology and circulating MMPs
Using Spearman rank correlation analysis, hepatic MMP expression was compared mutually and with the following parameters: histological grading and staging, hepatic mRNA expression of TIMP-1, -2 and -3, procollagen type I and IV, laminin, circulating protein concentrations of corresponding MMPs, TIMP-1 and -2, and hyaluronate.
Correlation coefficients and the corresponding significances are shown in Table 2 . Two clusters of closely correlated MMPs were identified (R = 0.6-0.9). The first group consisted of MMP-3, -11 and -13, and the second group comprised MMP-2, -7 and -14 and the less closely associated MMP-1 (Table 2A ). The latter group were closely correlated with the hepatic mRNA expression of TIMP-1, -2 and -3, procollagens type I and IV and laminin (R = 0.5-0.8; Table 2B ). This relation to fibrosis-associated protein expression was confirmed by comparison with the histological staging (R = 0.6-0.7). However, when patients with established liver cirrhosis were excluded from the correlation analysis, the associations between MMP-2, -7 and -14 and parameters of fibrotic liver disease were less closely correlated.
With the exception of MMP-2, no strong correlation between hepatic mRNA expression and the corresponding circulating pro-MMP levels was found. Interestingly, hepatic mRNA levels of MMP-2, -7 and -14 were strongly correlated with circulating plasma levels of TIMP-1 and hyaluronate (R = 0.5-0.8), further strengthening their relation to fibroproliferation.
MMP-3(− 1171) promoter polymorphism and hepatic MMP-3 expression in chronic hepatitis C
Since hepatic MMP-3 mRNA levels were highly variable without correlation to the disease stage (see Figures 1  and 2 ), we analysed whether genetic factors influenced MMP-3 expression in chronic hepatitis C. A previously reported MMP-3 promoter polymorphism at position − 1171 relative to the transcription start site [25] causes a variation of a polymonomeric track of adenosines with five adenosines (5A) in one allele and six adenosines (6A) in the other.
The hepatic MMP-3 mRNA expression decreased 10-fold when patients with genotype 5A/5A were compared with patients with genotypes 5A/6A and 6A/6A (223 + − 65, 127 + − 37 and 22 + − 8 MMP-3 equivalents/ng of mRNA respectively; P < 0.05 as determined by a multivariate analysis; means + − S.E.M.). Table 3 shows the genotype distribution of the MMP-3 promoter polymorphism in patients with hepatitis C Table 2 Correlation analysis for hepatic MMP mRNA expression in chronic hepatitis C (A) Correlation coefficients between hepatic mRNA expression of the different MMPs were calculated using Spearman rank analysis. (B) Hepatic mRNA expression of MMPs was correlated to the total inflammatory activity (grading) and fibrotic changes (staging) of the liver [19] , hepatic mRNA expression of TIMP-1, -2 and -3, procollagen type I α-1 chain, type IV α-1 chain and laminin B1 chain, and to serum/plasma levels of hyaluronate, TIMP-1 and -2 and circulating MMP concentrations. In (A) and (B), pairs of correlation coefficients (R ) and significances (P) of Spearman ranking for two groups are shown: a) all patients (including end-stage cirrhosis), where prevalence of cirrhosis was 31 % (n = 36); and b) all cirrhotic livers were excluded, where prevalence of mild fibrosis was 36 % (n = 25). P values below 0.05 were considered to be significant. n.s., not significant, n.d., not determined. and in controls. The proportion of 5A/5A homozygous carriers varied between 23 % in chronic hepatitis C and 32 % in controls. ORs were calculated to compare controls, chronic hepatitis patients and patients with HCV-induced liver cirrhosis. However, with the numbers of patients examined, no significant differences between the study groups were found.
DISCUSSION
The detection of matrix-degrading activity in liver tissue gave rise to the concept of fibrosis as a disturbed balance between matrix production and degradation [28] . Initial experiments suggested that the collagenolytic activity disappears with the progression to the stage of liver cirrhosis [29] [30] [31] . These data were complemented with the observation that TIMP-1 is up-regulated in liver fibrosis [32, 33] . However, the model of a down-regulated MMP activity leading to irreversible fibrosis does not appear to be sufficient. First, we are faced with an expanding family of MMPs and TIMP which cannot be assumed to be regulated identically [5] [6] [7] [8] . Secondly, experimental work and human studies have shown convincingly that some MMPs are up-and not down-regulated in liver cirrhosis [13] [14] [15] 17, 34, 35] . Thirdly, the functions ascribed to MMPs expand beyond the degradation of extracellular matrix. MMPs are involved in extracellular protein modification, i.e. activation of pro-MMPs, and in protein shedding from the cell surface. Furthermore, degradation of specific ECM components may act profibrogenically by the release of ECM-bound cytokines such as transforming growth factor-β. A modified ECM may also directly influence the cellular phenotype. One candidate protein which potentially mediates HSC activation induced by changes in the extracellular environment could be focal adhesion kinase [36, 37] .
The aim of our present study was to give a comprehensive overview on MMP gene expression during the development of chronic liver disease from the initial non-fibrotic stages to decompensated liver cirrhosis. Chronic hepatitis C was chosen as a model, because of its homogeneous organ involvement and clear-cut diagnostic criteria, including a well-defined histological scoring system [19] . Furthermore, fibrosis regression has been demonstrated after treatment of hepatitis C [38, 39] , pointing to the role of matrix degradation in this disease.
The current literature on MMP expression in chronic human liver disease is limited. Several papers analysed MMP-1 and -2 expression, demonstrating both to be upregulated in fibrosis [14, 15, 35, 40] . In addition, data on hepatic MMP-7 and -14 mRNA expression have been reported [17, 35] ; however, the number of patients included in these studies were mostly small. With the exception of an analysis by Takahara et al. [35] , the development of MMP expression through different disease stages has not yet been addressed. In addition, most studies were limited by the use of semi-quantitative methods, i.e. Northern blotting or ribonuclease protection assay. None of these procedures was evaluated with regard to their intra-assay and inter-assay variability. Thus the current knowledge on MMP expression in chronic liver disease is rather vague.
Our present study analysed the hepatic mRNA expression of eight different MMPs in human liver with respect to the different stages of fibrotic organ damage. To allow quantitative analysis, we have developed competitive RT-PCR assays, which were standardized and evaluated according to good laboratory practice procedures.
We were able to define differentially regulated MMP subsets. mRNA expression of the first subset, notably MMP-1, -2, -7 and -14, increased with the progression of liver fibrosis. The increase was paralleled by the activation of genes typically expressed in fibrosis, e.g. procollagens, laminin and TIMP. Both the ECM genes and the abovementioned MMPs are known to be expressed by activated HSCs [15, [40] [41] [42] . Interestingly, the increase in MMP expression exceeded the increase of both ECM and TIMP gene expression 10-fold. This should shift the balance between matrix production and degradation towards degradation, especially since MMP-14 is up-regulated, which is involved in the activation cascade of other MMPs. The parallel increase of MMP expression and fibrosis stage therefore argues for a profibrogenic role for this MMP group.
A second group of MMPs (i.e. MMP-11 and -13) showed a strong, but transient, increase during the course of chronic hepatitis C. To a lesser extent, MMP-9 followed this course. The transient type of up-regulation is compatible with the hypothesis that a loss of MMP expression in late stages of fibrosis contributes to its irreversibility. So far, no comparable data describing distinct MMPs have been reported by other investigators. Although MMP-13 may derive from activated HSCs [32] , the pattern of up-regulation does not resemble that of other HSC-associated genes. Therefore the cellular source of the transiently expressed MMPs remains unclear.
Interestingly, hepatic MMP-3 expression was highly variable, but not clearly related to the disease stage. We therefore analysed the impact of the MMP-3(− 1171) promoter polymorphism on MMP-3 gene expression. The polymorphism emerged as a major determinant of hepatic MMP-3 expression. An additional analysis of the prevalence of the polymorphic MMP-3 loci in patients with chronic hepatitis C and in HCV-induced liver disease did not reveal a relation between MMP-3 and the development of liver cirrhosis. Thus our present data could not link hepatic MMP-3 expression and fibrosis in chronic hepatitis C.
Ample data have been reported analysing the diagnostic value of circulating MMPs for the detection of liver cirrhosis [43] [44] [45] . However, it was never proved that circulating levels actually represent the hepatic expression levels. We therefore used our expression data to evaluate circulating MMPs as diagnostic tools. With the exception of MMP-2, no significant correlations were found. In contrast, circulating parameters of liver fibrosis (e.g. TIMP-1 and -2 and hyaluronate) correlated with the hepatic expression of fibrosis-associated MMPs. The level of circulating proteins may be influenced by many factors: (i) there needs to be a significant spillover at the site of production; (ii) protein degradation results in highly variable half-lives of different proteins; and (iii) concentrations may be influenced by protein production at other sites. As an example, we have shown previously [24] that circulating blood cells (especially mononuclear cells) change their expression pattern of MMPs and TIMP in HCV infection. For the indicated reasons, circulating MMP levels may not adequately reflect hepatic MMP expression. This is especially the case for MMPs with low-level hepatic expression such as MMP-1.
In conclusion, we were able to clarify the currently rather diffuse picture of MMP gene regulation during the course of human chronic liver disease. MMP expression in chronic hepatitis C appears as a differentially regulated process closely dependent on the stage of the disease. In part, MMP up-regulation appears to depend on the activation of HSCs. Further studies will be required to confirm this and should address the cellular basis of the transiently expressed MMPs. Now that the stagedependent behaviour of MMP expression is clearer, functional studies of their proposed pro-and antifibrogenic potential need to be performed.
